

ROS


The transmembrane proto-oncogene receptor tyrosine kinase (RTK) ROS is one of the last two remaining orphan receptor tyrosine kinases. Its normal expression pattern is tightly spatiotemporally restricted during development. The ectopic expression, as well as the production of variable mutant forms of ROS kinase, has been reported in a number of cancers, such as glioblastoma multiforme, and non-small cell lung cancer, suggesting a role for ROS kinase in deriving such tumors. It is thought also that the c-ROS gene may have a role in some cardiovascular diseases, and the fact that homozygous male mice targeted against the c-ROS gene are healthy but infertile has inspired researchers to think about ROS inhibition as a method for the development of new male contraceptives.

ROS1 is a transmembrane receptor tyrosine kinase proto-oncogene that has been shown to have rearrangements with several genes in glioblastoma, non-small-cell lung cancer (NSCLC), and other neoplasms, including intrachromosomal fusion with GOPC due to microdeletions at 6q22.1. ROS1 fusion events are important findings in these tumors, as they are potentially targetable alterations with newer tyrosine kinase inhibitors.

ROS Inhibitors, Activators, Modulators & Inducers

ALK/ROS1-IN-1		Antibacterial agent 69	
ALK/ROS1-IN-1 (compound 2e) is a potent and selective anti crizotinib-resistant ALK/ROS1 dual inhibitor, with IC _{so} s of 0.174 μ M and 0.530 μ M for ALK and ROS1 enzyme, respectively.	Cat. No.: HY-130794	Antimicrobial agent 69 is a novel structural antimicrobial regulator and has been used to fight deadly multidrug-resistant bacterial infections, and its < b > MICs < / b > value is 2.978 μ M.	Cat. No.: HY-144252
Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	u.,	Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	ун
Antibacterial agent 70	Cat. No.: HY-144255	Anticancer agent 15	Cat. No.: HY-139860
Antibacterial agent 70 is a new dihydropyrimidinone imidazole hybrid antibacterial agent, and its < b > MIC < / b > value is 0.5 μg/mL.		Anticancer agent 15 is capable of significantly increasing the cellular level of ROS and inducing melanoma cancer cell death via necroptosis.	
Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	o∕¬NH ⊱N o∕	Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	
Anticancer agent 42	Cat. No. : HY-146516	Antitumor agent-55	Cat. No. : HY-146038
Anticancer agent 42 (compound 10d) is an orally active anticancer agent, and shows a potent antitumor activity against MDA-MB-231 cell with an IC_{50} of 0.07 μ M. Anticancer agent 42 can exert its anticancer activity by activating apoptotic pathway and p53 expression.Purity:>98%Clinical Data:No Development Reported Size:1 mg, 5 mg		Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC_{50} of 0.91 μ M. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3.Purity:>98%Clinical Data:No Development Reported Size:1mg, 5mg	
Apogossypolone (ApoG2)	Cat. No .: HY-19551	Capillarisin	Cat. No. : HY-121192
Apogossypolone (ApoG2) is an orally active Bcl-2 family proteins inhibitor with K ₁ values of 35, 25 and 660 nM for Bcl-2, Mcl-1 and Bcl-X ₁ , respectively. Apogossypolone shows antitumor activities, induces cell apoptosis and autophagy . Apogossypolone also has antifungal activity.		Capillarisin, as a constituent from Artemisiae Capillaris herba, is found to exert anti-inflammatory and antioxidant properties.	но странование он останование он он о
Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg		Purity:>98%Clinical Data:No Development ReportedSize:5 mg, 10 mg, 25 mg	
Capsanthin	Cat. No.: HY-125711	Chol-CTPP	Cat. No. : HY-144825
Capsanthin is a carotenoid that has been found in C. annuum. Capsanthin has antioxidantantitumor and anti-inflammatory effects.	"" for the second secon	Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP).	"operation of the second
Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg		Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	

Cinnamtannin B-1		Crizotinib	
	Cat. No.: HY-130237	(PF-02341066)	Cat. No.: HY-50878
Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects. Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo.		Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively.	
Purity: ≥95.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg	но СР НО СР	Purity: 99.97% Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg	g, 500 mg
Crizotinib hydrochloride (PF-02341066 hydrochloride)	Cat. No. : HY-50878A	Crizotinib-d5 (PF-02341066-d5)	Cat. No.: HY-50878S
Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC ₅₀ s of 20 and 8 nM, respectively.		Crizotinib-d5 (PF-02341066-d5) is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC ₅₀ s of 20 and 8 nM, respectively.	
Purity: 99.86% Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg	mg, 500 mg	Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	
Derrone	Cat. No.: HY-N3737	Entrectinib (NMS-E628; RXDX-101)	Cat. No.: HY-12678
Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC _{so} values of 6 and 22.3 μ M against Aurora B and Aurora A , respectively. Derrone shows anti-tumor activity.		Entrectinib (NMS-E628) is a potent, orally available, and CNS-active pan-Trk , ROS1 , and ALK inhibitor. Entrectinib inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC_{50} values of 1, 3, 5, 12 and 7 nM, respectively. Antitumor activity.	
Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg	,	Purity: 99.32% Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg	
F-1	Cat. No. : HY-112801	Fascaplysin	Cat. No.: HY-112328
F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC ₅₀ s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK ^{WT} , ROS1 ^{WT} , ALK ^{L1196M} and ALK ^{G1202R} , respectively.		Fascaplysin is an antimicrobial and cytotoxic red pigment, that can come from the marine sponge (Fascaplysinopsis sp.). Fascaplysin has been synthesized in seven steps from indole (65% yield).	
Purity:98.65%Clinical Data:No Development ReportedSize:5 mg, 10 mg, 25 mg, 50 mg, 100 mg		Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	
GGTI-2154	Cat. No. : HY-16229	GGTI-2154 hydrochloride	Cat. No.: HY-16229A
GGTI-2154 is a potent and selective inhibitor of geranylgeranyltransferase I (GGTase I), with an IC_{50} of 21 nM. GGTI-2154 shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 can be used for the research of cancer.		GGTI-2154 hydrochloride is a potent and selective inhibitor geranylgeranyltransferase I (GGTase I), with an IC ₅₀ of 21 nM. GGTI-2154 hydrochloride shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 hydrochloride can be used for the research of cancer.	N NH H H-CI
Purity:>98%Clinical Data:No Development ReportedSize:5 mg, 10 mg, 25 mg, 50 mg, 100 mg		Purity:98.13%Clinical Data:No Development ReportedSize:5 mg, 10 mg, 25 mg, 50 mg, 100 mg	



Nrf2/HO-1-IN-1		Orniplabin	
	Cat. No.: HY-146971	(SMTP-7)	Cat. No.: HY-122311
Nrf2/HO-1-IN-1 is a potent Nrf2/HO-1 pathway inhibitor, with an IC ₅₀ value of 0.38 μM for NO. Nrf2/HO-1-IN-1 can significantly reduce the level of ROS in cells. Nrf2/HO-1-IN-1 can be used for researching anti-inflammatory. Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg		Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg	
р38 МАРК-IN-3	Cat. No.: HY-144697	Phyltetralin	Cat. No. : HY-121397
p38 MAPK-IN-3 (Compound 2c) is a p38α MAPK inhibitor. p38 MAPK-IN-3 has antitumor activities and induces apoptosis and ROS .	J.C. C. C. C. Br	Phyltetralin (Compound 10) is a natural product than can be isolated from the hexane-ethyl acetate extract of Phyllanthus amarus leaves. Phyltetralin possesses immunosuppressive effects on different lineages of innate immune system.	
Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg		Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg	
Repotrectinib		Taletrectinib	
(TPX-0005)	Cat. No.: HY-103022	(DS-6051b; AB-106)	Cat. No.: HY-131003
Repotrectinib (TPX-0005) is a potent ROS1 (IC_{s0} =0.07 nM) and TRK (IC_{s0} =0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC_{s0} =1.01 nM). Repotrectinib has anti-cancer activity.		Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC_{50} s of 0.207, 0.622, 2.28, and 0.98 nM, respectively.	
Purity: 99.81% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg		Purity: 99.96% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 7	ö 100 mg
Taletrectinib free base		Topo I-IN-1	
(DS-6051b free base; AB-106 free base)	Cat. No.: HY-131003A		Cat. No.: HY-145859
Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC ₅₀ s of 0.207, 0.622, 2.28, and 0.98 nM, respectively.		Topo I-IN-1 (Compound 14d) is a potent Topo I inhibitor with antitumor activity and DNA intercalative capability. Topo I-IN-1 induces cell apoptosis .	HN O NH
Purity:>98%Clinical Data:Phase 2Size:1 mg, 5 mg	-	Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	Ϋ́Η Ο
Topoisomerase I/II inhibitor 3	Cat. No.: HY-146504	Tubulin polymerization-IN-6	Cat. No. : HY-146505
Topoisomerase I/II inhibitor 3 (compound 7) is a potent topoisomerase I (Topo I) and II (Topo II) dual inhibitor. Topoisomerase I/II inhibitor 3 can inhibit cell proliferation, invasion and migration, and induce apoptosis by inhibiting PI3K /Akt/mTOR signaling pathway.		Tubulin polymerization-IN-6 (compound 5f) is a potent tubulin polymerization inhibitor, with an IC_{50} of 1.09 μ M. Tubulin polymerization-IN-6 inhibits cell migration and tube formation and contributes to the anti-angiogenesis.	
Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg	\bigcirc	Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	Ĭ Ŏ

www.MedChemExpress.com

VEGFR-2-IN-19	Cat. No.: HY-146367	WY-135	Cat. No .: HY-111416
VEGFR-2-IN-19 (Compound 15b) is a potent VEGFR2 inhibitor. VEGFR-2-IN-19 induces cell apoptosis and increases intracellular reactive oxygen species level. VEGFR-2-IN-19 can be used as an anticancer agent.		WY-135 is an ALK (IC $_{\rm 50}$ = 1.4 nM) and ROS1 (IC $_{\rm 50}$ = 1.1 nM) dual inhibitor.	Q Q X N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg		Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	
β-Carotene		β-Nor-lapachone	
(Provitamin A; beta-Carotene)	Cat. No.: HY-N0411		Cat. No.: HY-146067
β-Carotene (Provitamin A), a carotenoid compound, is a naturally-occurring vitamin A precursor. β-Carotene is a modulator of reactive oxygen species (ROS) , with antioxidant and antiinflammatory activities.	Xurruny	β-Nor-lapachone is a Candida glabrata antibiofilm agent. β-Nor-lapachone can stimulate ROS production, inhibits efflux activity, adhesion, biofilm formation and the metabolism of mature biofilms of Candida glabrata. β-Nor-lapachone has antifungal activity.	
Purity: ≥98.0% Clinical Data: Launched Size: 50 mg, 100 mg		Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg	п О